NASDAQ · CORT
Corcept Therapeutics Incorporated
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CORT: Nov 03, 2026
Corcept Therapeutics Incorporated Common Stock is expected to report earnings on 11/03/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $0.68. The reported EPS for the same quarter last year was $0.16.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.68 | $0.78 | $0.61 | 3 |
| Dec 2026 | $0.98 | $1.31 | $0.68 | 3 |
| Mar 2027 | $0.43 | $0.74 | $0.11 | 3 |
| Jun 2027 | $0.78 | $1.03 | $0.51 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · Zacks- RTTNews · Oct 26, 9:00 AM EDTCorcept Reports Positive Phase 2 BELLA Results For Lifyorl In Platinum-Resistant Ovarian Cancer(RTTNews) – Corcept Therapeutics Incorporated (CORT) reported positive results from Part A of its Phase 2 BELLA trial evaluating Lifyoril (relacorilant) in combination with nab-paclitaxel and bevacizumab in patients with platinum-resistant ovarian cancer, a form of the disease th
- BNK Invest · Oct 20, 3:30 PM EDTNotable Tuesday Option Activity: IREN, HTZ, CORTLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IREN Ltd (Symbol: IREN), where a total volume of 351,428 contracts has been traded thus far today, a contract volume which is representative of approximately 35.
- Zacks · Oct 19, 8:50 AM EDTCan Lifyorli Aid Corcept's Long-Term Growth Prospects Beyond Korlym?CORT banks on newly approved drug, Lifyorli, while potential new approvals and clinical studies could help diversify revenues beyond Korlym.
- Zacks · Oct 19, 8:00 AM EDTThe Zacks Analyst Blog Highlights Ross Stores, Roku, APA, Corcept Therapeutics and Halozyme TherapeuticsRoss Stores, Roku, APA, Corcept Therapeutics and Halozyme Therapeutics earn top Zacks rankings, backed by growth drivers ranging from streaming ads to drug demand.
- Zacks · Oct 16, 4:30 AM EDTBuy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 GainsROST, ROKU, APA, CORT and HALO are five non-tech Nasdaq stocks riding strong growth trends and rising earnings estimates, positioning them for potential gains in Q4.
- Zacks · Oct 15, 2:32 PM EDT3 Low-Beta Defensive Stocks to Buy as Inflation Continues to SurgeAs inflation surges on rising energy costs, CAH, UNH and CORT stand out as low-beta healthcare stocks with strong expected earnings growth and defensive appeal.
- Zacks · Oct 15, 11:56 AM EDTFDA Expands ImmunityBio's Anktiva Label in Bladder CancerIBRX wins expanded FDA approval for Anktiva plus BCG, covering all patients with BCG-unresponsive NMIBC and broadening its commercial opportunity.
- Zacks · Oct 15, 10:04 AM EDTHere's Why You Should Add EYPT Stock to Your Portfolio NowEyePoint's Duravyu faces a key LUCIA study data readout in late 2026, with results potentially paving the way for an NDA filing in 2027.
- Zacks · Oct 15, 9:33 AM EDTRARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekUltragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.
- Zacks · Oct 15, 8:40 AM EDTAre Medical Stocks Lagging Aspen Pharmacare (APNHY) This Year?Here is how Aspen Pharmacare (APNHY) and Corcept Therapeutics (CORT) have performed compared to their sector so far this year.
- Zacks · Oct 14, 12:38 PM EDTLQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia LabelLiquidia settles six legal disputes with United Therapeutics, securing Yutrepia access for PAH patients but facing $380.7 million in payments and a narrower drug label.
- Zacks · Oct 14, 12:31 PM EDTHumana's CenterWell Expansion Gets a Boost From BlackRock's CapitalHUM's CenterWell venture with BlackRock brings $2.8 billion in capital, easing balance sheet liabilities and supporting clinic expansion.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Corcept Therapeutics Incorporated from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.